)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Achilles Therapeutics
Achilles Therapeutics (ACHL) investor relations material
Achilles Therapeutics has been delisted
Achilles Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary14 Nov, 2024
Executive summary
Discontinued TIL-based cNeT program and closed Phase I/IIa CHIRON and THETIS trials; exploring strategic options with BofA Securities as advisor.
Cash position of $86.1 million as of September 30, 2024, plus $12.8 million R&D tax credit received in October.
Financial highlights
Cash and cash equivalents declined to $86.1 million from $131.5 million at year-end 2023.
R&D expenses rose to $16.4 million in Q3 2024 from $14.7 million in Q3 2023.
G&A expenses decreased to $4.0 million in Q3 2024 from $4.4 million in Q3 2023.
Net loss widened to $19.6 million ($0.48/share) in Q3 2024 from $16.7 million ($0.42/share) in Q3 2023.
Comprehensive loss for Q3 2024 was $13.5 million, reflecting a $6.1 million foreign exchange gain.
Outlook and guidance
Management is reviewing strategic options, including engagement with third parties developing alternative modalities for targeting clonal neoantigens.
Forward-looking statements highlight expectations for cash runway, operating expenses, and capital requirements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Achilles Therapeutics
Achilles Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Achilles Therapeutics plc is a biopharmaceutical company based in the United Kingdom, focused on developing precision T cell therapies targeting cancer. Using its proprietary platform, Achilles designs therapies that target clonal neoantigens—unique markers on tumor cells—enabling a personalized approach to treatment. The company’s therapeutic programs are primarily aimed at treating solid tumors, including lung and melanoma cancers. The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.